Bi-annual CDTI
PreclinicalSmall molecule
Bi-annual CDTI is one of 9 small molecule programs targeting Onchocerciasis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Onchocerciasis
#DrugCompanyPhaseTrials
1Stromectol
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Rifadin
SanofiApproved
Cydectin
MMedicines Development for Global Health
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Emodepside
JJennifer Keiser
Phase 2
Albenza
IImpax Laboratories, LLC
Preclinical
Hetrazan
WWyeth-Lederle Vaccines
Preclinical
Bi-annual CDTI
UUniversiteit Antwerpen
Preclinical
Praziquantel /kg
OOswaldo Cruz Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bi-annual CDTI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversiteit Antwerpen